Study Validates RainDance's Microdroplet PCR Technology for Targeted Resequencing | GenomeWeb

NEW YORK (GenomeWeb News) – A study published in the November issue of Nature Biotechnology has found that RainDance Technologies' microdroplet-based PCR method is well suited for large-scale targeted resequencing studies, and more scalable than the "gold standard" of traditional PCR for that application.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.